CRIMEAN CONGO HEMORRHAGIC FEVER: A LOOMING THREAT
AbstractEid al Adha during CCHF transmission seasons poses a threat of exposing large population to this viral haemorrhagic fever. CCHF was first reported inCrimeain 1944. Oral ribavirin and general supportive therapy is the mainstay of treating CCHF case. Eid al Adha is a unique epidemiological event which shifts the risk of CCHF infection from high risk population to general population. During Eid, the prevention efforts must focus on reducing the risk of tick to human transmission, animal to human transmission and control of CCHF in animals and ticks
WHO. Crimean-Congo haemorrhagic fever. [Internet]. 2013[cited 2016 Aug 21]. Available from: http://www.who.int/mediacentre /factsheets/fs208/en/.
Maltezou HC, Maltezos E, Papa A. Contact tracing and serosurvey among healthcare workers exposed to Crimean-Congo hemorrhagic fever in Greece. Scand J Infect Dis 2009;41(11-12):877–80.
Aslam S, Latif MS, Daud M, Rahman ZU, Tabassum B, Riaz MS, et al. Crimean Congo hemorrhagic fever: Risk factors and control measures for the infection abatement. Biomed Rep 2016;4(1):15–20.
Ergönül O. Crimean-Congo hemorrhagic fever virus: New outbreaks, new discoveries. Curr Opin Virol 2012;2(20:215–20.
National Institute of Health. Guidelines for Crimean-Congo Hemorrhagic Fever (CCHF). [Internet]. 2013 [cited 2016 Aug 29]. Available from: http://www.phc.org.pk/downloads/CCHF%20guidelines%20September%202013.pdf
Shepherd AJ, Swanepoel R, Shepherd SP, McGillivray GM, Searle LA. Antibody to Crimean-Congo hemorrhagic fever virus in wild mammals from southern Africa. Am J Trop Med Hyg 1987;36(1):133–42.
Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979;15(4):307–417.
Maltezou HC, Papa A. Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment. BMC Med 2011;9:131.
Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res 2011;90(2):85–92.
Mardani M, Jahromi MK, Naeni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. Clin Infect Dis 2003;36(12):1613–8.
Karlberg H, Lindegren G, Mirazimi A. Comparison of antiviral activity of recombinant and natural interferons against Crimean-Congo hemorrhagic fever virus. Open Virol J 2010;4:38–41.
Whitehouse CA. Risk groups and control measures for Crimean-Congo hemorrhagic fever. In: Ergonul O, Whitehouse CC, editors. Crimean-Congo Hemorrhagic Fever Netherlands. Springer; 2007. p.273–80.
Leblebicioglu H, Sunbul M, Memish ZA, Al-Tawfiq JA, Bodur H, Ozkul A, et al. Consensus report: preventive measures for Crimean-Congo hemorrhagic fever during Eid-al-Adha festival. Int J Infect Dis 2015;38:9–15.